The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...

The solution leverages AI to match molecular, demographic, and clinical history data against eligibility criteria from active trials. Credit: MUNGKHOOD STUDIO / Shutterstock.com. Anova Enterprises has ...

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...

MSD’s T-cell engager, MK-1045, has demonstrated its tolerability and efficacy in a Phase Ib/II study in B-cell acute lymphocytic leukaemia (B-ALL). Image credit: HJBC via Shutterstock.com. MSD said ...

ARCH Ventures-backed Paradigm Health has acquired Roche-owned Flatiron Health’s clinical research business, while closing an oversubscribed $78m Series B financing round to incorporate clinical trials ...

Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

Capricor’s stock shot up by 371% after it announced the HOPE-3 data. Image credit: Lightspring / Shutterstock.com. Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of ...

Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...